MedTrace Logo

To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines

NCT01791920 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 262

Last updated 2022-04-15

No results posted yet for this study

Summary

To compare the safety and efficacy of Botulax® with Botox® in the improvement of moderate to severe glabellar lines.

Conditions

  • Skin Aging

Interventions

DRUG

Botulinum toxin type A(Botulax®)

Single administration, Day 0, 20 units

DRUG

Botulinum toxin type A(Botox®)

Single administration, Day 0, 20units

Sponsors & Collaborators

  • Hugel

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-12-31
Completion
2012-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01791920 on ClinicalTrials.gov